Examkin

Soru

Zorluk: OrtaPulmonary and Critical Care

A 61-year-old man with a history of chronic obstructive pulmonary disease and ischemic cardiomyopathy is evaluated in the intensive care unit. He was intubated 6 days ago for acute respiratory failure. Three days ago, he developed a temperature of 38.9°C (102.0°F), increased purulent endotracheal secretions, and a new right lower lobe consolidation on his chest radiograph. A diagnosis of ventilator-associated pneumonia was made, and empiric therapy with intravenous vancomycin, cefepime, and amikacin was initiated. Today, his temperature is 37.4°C (99.3°F), and his oxygenation has improved. Endotracheal aspirate cultures obtained prior to antibiotic initiation grow Klebsiella pneumoniae. Susceptibility testing shows the isolate is resistant to ampicillin but susceptible to ceftriaxone, cefepime, and meropenem. Which of the following is the most appropriate next step in management?

  1. Discontinue vancomycin and amikacin, and transition to intravenous ceftriaxoneCevap
  2. B
    Continue the current regimen of intravenous vancomycin, cefepime, and amikacin
  3. C
    Discontinue vancomycin and amikacin, and transition to intravenous meropenem
  4. D
    Discontinue antibiotics and initiate intravenous furosemide and systemic corticosteroids
  5. E
    Obtain an arterial blood gas to apply Winter's formula for ventilator titration

Cevap

Discontinue vancomycin and amikacin, and transition to intravenous ceftriaxone
The patient has confirmed ventilator-associated pneumonia (VAP) caused by Klebsiella pneumoniae. According to antimicrobial stewardship principles, empiric broad-spectrum therapy should be narrowed once definitive culture and susceptibility data are available. Vancomycin (MRSA coverage) and amikacin (second anti-pseudomonal agent) can be safely discontinued. Cefepime, a fourth-generation cephalosporin with anti-pseudomonal activity, should be de-escalated to ceftriaxone, a narrower third-generation cephalosporin that is fully active against this specific isolate.

Adım Adım Çözüm

1
Diagnose the patient's current clinical trajectory based on presentation and laboratory data.
The patient is improving from ventilator-associated pneumonia (VAP) definitively caused by Klebsiella pneumoniae.
The initial fever, purulent secretions, and consolidation confirmed VAP, and the endotracheal cultures have now identified the specific causative pathogen.
2
Analyze the antibiotic susceptibility profile of the isolated organism.
The K. pneumoniae isolate is susceptible to ceftriaxone, cefepime, and meropenem.
Reviewing sensitivities is necessary to tailor the antibiotic regimen away from broad empiric coverage.
3
Select the most targeted antibiotic therapy.
De-escalate to ceftriaxone.
Ceftriaxone provides narrow, adequate coverage for the Klebsiella isolate, allowing discontinuation of anti-MRSA (vancomycin) and broad anti-pseudomonal (amikacin, cefepime) coverage.

Anahtar Kavram

Antimicrobial stewardship in the ICU requires de-escalating empiric broad-spectrum antibiotic regimens to the narrowest effective therapy once culture and susceptibility results are available.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pulmonary and Critical Care

Bu konudan daha fazla soru